PT  - JOURNAL ARTICLE
AU  - Payen, Didier
AU  - Cravat, Maxime
AU  - Maadadi, Hadil
AU  - Didelot, Carole
AU  - Prosic, Lydia
AU  - Dupuis, Claire
AU  - Losser, Marie-Reine
AU  - De Carvalho Bittencourt, Marcelo
TI  - A longitudinal study of immune cells in severe COVID-19 patients
AID  - 10.1101/2020.06.16.20130914
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.16.20130914
4099  - http://medrxiv.org/content/early/2020/06/19/2020.06.16.20130914.short
4100  - http://medrxiv.org/content/early/2020/06/19/2020.06.16.20130914.full
AB  - Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2-specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR expression was below the 8,000 AB/C threshold defining acquired immunodepression. A “V” trend curve for lymphopenia, monocyte numbers, and HLA-DR expression was observed with a nadir between days 11-14 after symptoms’ onset. Intermediate CD14++CD16+ monocytes increased early with a reduction in classic CD14++CD16- monocytes. Polyfunctional SARS-Cov-2-specific CD4 T-cells were present and functional, whereas virus-specific CD8 T-cells were less frequent and not efficient. We report a temporal variation of both innate and adaptive immunity in severe COVID-19 patients, helpful in guiding therapeutic decisions (e.g. anti-inflammatory vs. immunostimulatory ones). We describe a defect in virus-specific CD8 T-cells, a potential biomarker of clinical severity. These combined data also provide helpful knowledge for vaccine design.Trial registration number NCT04386395Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04386395Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethical Committee (Saisine 263) of CHRU-Nancy.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailability of data referred to in the manuscript will be evaluated on an each individual basis.